Severance Hospital

S.BIOMEDICS completes brain transplant of hESC-derived dopaminergic progenitors (TED-A9) for Phase 1/2a study in patients with Parkinson’s disease

Retrieved on: 
木曜日, 2月 29, 2024
Stem Cells, Data Management, Biotechnology, Technology, Health, Neurology, Research, Hospitals, Surgery, Science, Clinical Trials, Severance Hospital, Dyskinesia, KOSDAQ, Safety, Neuron, Yonsei University, DLT, Freezing, Cell, Parkinson's disease, Transplant, Putamen, Patient, Clinical trial, Gait, Brain, Pharmaceutical industry

S.BIOMEDICS Co., Ltd. (KOSDAQ: 304360) announced that it has successfully completed the brain transplant of TED-A9 (hESC-derived dopaminergic progenitors) for Phase 1/2a study for treating Parkinson's disease.

Key Points: 
  • S.BIOMEDICS Co., Ltd. (KOSDAQ: 304360) announced that it has successfully completed the brain transplant of TED-A9 (hESC-derived dopaminergic progenitors) for Phase 1/2a study for treating Parkinson's disease.
  • The primary objective of the Phase 1/2a trial is to assess the safety and exploratory efficacy of TED-A9 transplantation for two years post-transplant.
  • “We have developed a fundamental therapeutic mechanism that directly replaces dopaminergic neurons lost in patients with Parkinson's disease.
  • TED-A9 could represent a fundamental treatment that surpasses current therapies, which only temporarily alleviate the symptoms of Parkinson’s disease,” he added.

J INTS BIO, Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, accepted for presentation at the upcoming American Association for Cancer Research 2024 meeting in USA (AACR 2024)

Retrieved on: 
月曜日, 2月 26, 2024
NSCLC, Traffic barrier, Severance Hospital, EGFR, ESMO, ASCO, Permeability, Catholic University of Korea, National Cancer Center, Hospital, Asan Medical Center, AACR, Society, University, Seoul National University Hospital, Patient, Clinical trial, Oncology, Mutation, Trial of the century, Cancer, Pharmaceutical industry

J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.

Key Points: 
  • J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.
  • The topic of the presentation is "Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI for 3rd generation EGFR-TKI resistant patients in EGFR mutated advanced/metastatic non-small cell lung cancer".
  • In August last year, J INTS BIO registered the first patient for the global Phase 1/2 clinical trial of 'JIN-A02' at Severance Hospital in Korea.
  • A J INTS BIO official said, "The global clinical trial for 'JIN-A02' is progressing well and is receiving interest in the global market."

J INTS BIO, Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, accepted for presentation at the upcoming American Association for Cancer Research 2024 meeting in USA (AACR 2024)

Retrieved on: 
月曜日, 2月 26, 2024
NSCLC, Traffic barrier, Severance Hospital, EGFR, ESMO, Multimedia, ASCO, Permeability, Catholic University of Korea, National Cancer Center, Hospital, Asan Medical Center, AACR, Society, University, Seoul National University Hospital, Patient, Clinical trial, Oncology, Mutation, Trial of the century, Cancer, Pharmaceutical industry

J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.

Key Points: 
  • J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.
  • The topic of the presentation is "Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI for 3rd generation EGFR-TKI resistant patients in EGFR mutated advanced/metastatic non-small cell lung cancer".
  • In August last year, J INTS BIO registered the first patient for the global Phase 1/2 clinical trial of 'JIN-A02' at Severance Hospital in Korea.
  • A J INTS BIO official said, "The global clinical trial for 'JIN-A02' is progressing well and is receiving interest in the global market."

ASOCIO Digital Summit 2023 Paves the Way for Future Digital Cooperation

Retrieved on: 
木曜日, 11月 16, 2023
Security, Mobile, Wireless, Other Technology, Technology, Online Privacy, Digital inclusion, LG Uplus, MarkAny, Organization, Information, Digital security, Digital technology, Government Digital Service, LG, Reserve, ASOCIO, Federation, Digital divide, SK Inc., Seamless, Severance Hospital, Digital, Sustainability, Face, Cryptocurrency, Life, Growth, Elice

ASOCIO Digital Summit 2023 , held for the first time in Korea in 23 years on November 14 and 15, concluded with resounding success.

Key Points: 
  • ASOCIO Digital Summit 2023 , held for the first time in Korea in 23 years on November 14 and 15, concluded with resounding success.
  • The ASOCIO Digital Summit is a private organization composed of IT associations from 24 Asian and Oceanian nations.
  • The ASOCIO Digital Summit is hosted by a different member nation, providing a platform for regional collaboration and knowledge exchange in the digital technology sector.
  • The Digital Asia Initiative encompasses 10 key agenda items: Spreading Digital Inclusion, Facilitating the Usage of Digital Technology in Life, Fostering IT Education for Growth, Encouraging IT Worker Mobility, Promoting Seamless and Cross-Border Digital Services, Stepping up Digital Security, Valuing Privacy, Establishing Digital Norms, Building a Sustainable Digital Society, and Strengthening Partnership for Digital Asia.

Gencurix Obtains Approval for Companion Diagnostic of Digital PCR-based EGFR Mutation Test

Retrieved on: 
水曜日, 6月 14, 2023
KRAS, CE, AACR, Takeda, Severance Hospital, ESR1, NGS, RT-PCR, Cancer, Business, BRAF, Janssen, Mutation, Research, PIK3CA, Certification, Strategy, MRD, Plasma, Korean Ministry of Culture, Bio-Rad Laboratories, Hospital, Acquisition, Patient, European, EGFR, Colorectal cancer, IVD, Samsung Medical Center, Amivantamab, POLE, Recurrence, PCR, Mobocertinib, Medical device, NSCLC, Food

SEOUL, South Korea, June 13, 2023 /PRNewswire/ -- Gencurix , a leading cancer molecular diagnostics company, has obtained approval from the Korean Ministry of Food and Drug Safety for its Droplex EGFR Mutation Test v2.

Key Points: 
  • SEOUL, South Korea, June 13, 2023 /PRNewswire/ -- Gencurix , a leading cancer molecular diagnostics company, has obtained approval from the Korean Ministry of Food and Drug Safety for its Droplex EGFR Mutation Test v2.
  • This product is a companion diagnostic test designed to detect EGFR mutations commonly found in NSCLC patients and guide the selection of appropriate targeted anticancer therapies based on the test results.
  • Compared to existing EGFR mutation tests using RT-PCR, this product demonstrates significantly higher sensitivity.
  • This is the second EGFR mutation test for which Gencurix has obtained approval.

Genexine Abstract on GX-188E and GX-I7 Triple Combination Therapy in HNSCC Is Released at 2023 ASCO Annual Meeting

Retrieved on: 
金曜日, 5月 26, 2023
Research, Pharmaceutical, Oncology, Consumer, Technology, Artificial Intelligence, Genetics, Clinical Trials, Science, Women, Biotechnology, Health, Survival rate, DNA, IIT, MPR, Neoadjuvant therapy, TIL, Neoplasm, Clinical trial, Quality of life, Head, Immunotherapy, PCR, Severance Hospital, Trial of the century, ASCO, Professor, American Society of Clinical Oncology, Patient, Cervical cancer, Division, Annual general meeting, HNSCC, HPV, Pembrolizumab, Smoking, Tumor microenvironment, Society, Human papillomavirus infection, Cancer, Safety, Pharmaceutical industry, Medical imaging

The study evaluated the DNA vaccine GX-188E (tirvalimogene teraplasmid) and the lymphopenia-correcting immune-oncology drug GX-I7 (efineptakin alfa) in combination with immune checkpoint inhibitor Keytruda® (pembrolizumab).

Key Points: 
  • The study evaluated the DNA vaccine GX-188E (tirvalimogene teraplasmid) and the lymphopenia-correcting immune-oncology drug GX-I7 (efineptakin alfa) in combination with immune checkpoint inhibitor Keytruda® (pembrolizumab).
  • The primary endpoint evaluated the major pathological response (MPR) and other evaluation criteria included safety, recurrence rate and survival rate.
  • All 11 patients who participated in the trial underwent surgery as planned after neoadjuvant therapy with no increase in surgical delay or surgical complications.
  • The results of this study will be presented in a poster session at the ASCO 2023 Annual Meeting, which will be held in Chicago from June 2 to 6, 2023.

WAYCEN, the first medical AI company to win 4 CES 2023 innovation awards "Proved K-Medtech"

Retrieved on: 
木曜日, 1月 5, 2023
Lung cancer, AME Publishing Company, Electronics, Research, Record, Artificial intelligence, CES, Smartphone, Odyssey Software (Mobile Device Management), Respiratory system, Deep learning, Digital, Metastasis, SCIE, Endo, Exhibition, Cough, CTA, Severance Hospital, AI, Software, Consumer Technology Association, Gangneung Asan Hospital, EBUS, Lymph, National Association Medical Staff Services, Engineering, Human, Endoscopy, Diagnosis, Medical device, Medical imaging, Industrial design

Company specialized in AI Medtech, WAYCEN, won CES innovation awards for two years in a row

Key Points: 
  • Company specialized in AI Medtech, WAYCEN, won CES innovation awards for two years in a row
    WAYCEN swept CES 2023 innovation awards with medical AI products, collaborated with the medical staff
    SEOUL, South Korea, Jan. 5, 2023 /PRNewswire/ -- The company specialized in AI Medtech, WAYCEN (CEO Kyungnam Kim) made splendid achievements of winning four CES innovation awards for the first time among medical AI companies ahead of 'CES 2023', the world's largest electronics exhibition, which will be held in Las Vegas, United States, in next January.
  • Winning two awards solely for the products utilizing the real-time image analysis technology is to highlight innovations in WAYCEN's medical AI solution lineup.
  • It speaks volumes within the medical industry that medical professionals and AI-specialized company jointly developed clinically useful products through technical verifications and accomplished such great performance.
  • Also, it is the AI medtech-specialized company that was selected as the "Country Representative Innovation Company 1000'" and "MEDTECH INNOVATOR APAC TOP 4".

Genexine reports encouraging top-line results of the Phase 1b/2 clinical trial with GX-I7 (efineptakin alfa) in refractory or recurrent (R/R) metastatic Triple Negative Breast Cancer

Retrieved on: 
火曜日, 6月 7, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Transfer, Oncology, NLR Air Transport Safety Institute, Lymphocytopenia, Immunotherapy, Goal, Company, TNBC, Society, American Society of Clinical Oncology, Safety, ORR, Admission, discharge, and transfer system, Severance Hospital, CEO, ASCO, KOSDAQ, Biopsy, Therapy, Cervical cancer, Pembrolizumab, Patient, DART, Review, DNA, Immune system, Judgement, Data analysis, Homeostasis, CPS, Particle-size distribution, CKD, Cancer, PD-L1, Pharmaceutical industry

Top-line data showed that GX-17 in combination with pembrolizumab was safe and well tolerated in the overall phase 1b/2 trial.

Key Points: 
  • Top-line data showed that GX-17 in combination with pembrolizumab was safe and well tolerated in the overall phase 1b/2 trial.
  • Observed ORRs with GX-17 in combination pembrolizumab were 15.7% (8/51) for phase 1b and 21.2% (7/33) for phase 2.
  • Of the 25 patients who had an evaluable PD-L1 from a biopsy sample, 40.0% (10/25) were PD-L1 positive (CPS10).
  • GX-I7 represents a new class of potential therapy for cancer patients and could become the first therapy to manage lymphopenia in cancer patients.

Samsung Receives FDA Clearance for AI Algorithms that Detect Lung Nodules in Chest X-rays

Retrieved on: 
木曜日, 10月 28, 2021
Radiology, General Health, Health, FDA, Medical Devices, Hospitals, Technology, Other Technology, Massachusetts General Hospital, Diagnosis, Cade, Apple Inc. v. Samsung Electronics Co., Hospital, Steven Novella, Patient satisfaction, Workflow, Patient, FDA, Wangjing Nan (S) station, Food, Samsung, Severance Hospital, Samsung Medical Center, Marketing, Vuno, Samsung Digital Imaging, Multimedia, Food and Drug Administration, Artificial intelligence, Lung cancer, Solution, PACS, Digital radiography, Health, AI, Medical device, Medical imaging

NeuroLogica Corp. today announced it has received Food and Drug Administration (FDA) 510(k) clearance for its Auto Lung Nodule Detection (ALND) tool.

Key Points: 
  • NeuroLogica Corp. today announced it has received Food and Drug Administration (FDA) 510(k) clearance for its Auto Lung Nodule Detection (ALND) tool.
  • View the full release here: https://www.businesswire.com/news/home/20211028005735/en/
    Chest radiograph without Auto Lung Nodule Detection (ALND) and chest radiograph with lung nodule marked.
  • Aiding the reader's diagnosis by indicating the location of suspected lung nodules on chest X-ray images (posteroanterior chest radiographs).
  • As part of our commitment to advancing diagnostic radiology using AI, Samsung is collaborating with Vuno, a leading developer of AI solutions in healthcare.